MedPath

Enlivex Therapeutics

Enlivex Therapeutics logo
🇮🇱Israel
Ownership
Public
Established
2005-10-01
Employees
49
Market Cap
-
Website
http://www.enlivex.com
Introduction

Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. The company was founded by Dror Mevorach on January 22, 2012 and is headquartered in Ness Ziona, Israel.

© Copyright 2025. All Rights Reserved by MedPath